Cabaletta Bio, Inc.

The momentum for this stock is not very good. Cabaletta Bio, Inc. is not very popular among insiders. Cabaletta Bio, Inc. is a mediocre stock to choose.

News

Reviewing LadRx (OTCMKTS:CYTR) & Cabaletta Bio (NASDAQ:CABA)

Ticker Report Cabaletta Bio (NASDAQ:CABA - Get Free Report) and LadRx (OTCMKTS:CYTR - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based...\n more…

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Simply Wall St We can readily understand why investors are attracted to unprofitable companies. For example, although...\n more…

Panagora Asset Management Inc. Takes $2.24 Million Position in Cabaletta Bio, Inc. (NASDAQ:CABA)

Zolmax Panagora Asset Management Inc. purchased a new stake in Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The...\n more…

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Globe Newswire PHILADELPHIA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell...\n more…

Cabaletta Bio price target raised by $20 at TD Cowen, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Several Headwinds Dragged Cabaletta Bio (CABA) in Q2

Insider Monkey Fred Alger Management, an investment management company, released its Alger Small Cap Growth Fund second quarter 2024 investor letter. A copy of the letter can be downloaded here. U.S. equities...\n more…